Video: Sitting Down With… John Tomtishen
October 7, 2026
Catalent’s John Tomtishen discusses his path into cell therapy and the evolving approaches to CMC, manufacturing, and commercialization
1 min read
False
Advertisement
Cell & Gene
Pregnancy After CAR T Shows Early Promise
By Mouj Hijazi
October 7, 2026
No autoimmune disease flares occurred across 14 pregnancies after CAR T-cell therapy, with 8 healthy babies born and 5 pregnancies ongoing.
3 min read
When CAR T Cells Linger in the Gut
By Mouj Hijazi
October 7, 2026
Persistent CAR T cells and widespread immune disruption may help explain a rare form of severe intestinal inflammation after BCMA-directed therapy
3 min read
Building a CAR-T CMC Strategy on a Limited Budget
By Kate Fynes
October 6, 2026
Early developers do not need a finalized commercial process before first-in-human studies, but they do need a clear plan for managing cost, scalability, comparability, and future manufacturing changes
7 min read
Development & Clinical
Cell & Gene
Interviews
Business & Trends
Technology & Manufacturing
Power List
Musings from The Power List: Fabian Gerlinghaus
October 1, 2026
Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made
3 min read
In vivo CAR‑T – Reimagining Immune Engineering with Direct Cell Reprogramming
September 30, 2026
How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy to new indications
10 min read
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
September 30, 2026
Fayuvi is authorized for pediatric patients with preserved neurodevelopmental function following a study comparing treated children with a natural history cohort
2 min read
Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169
September 28, 2026
Phase I study will test whether a targeted lentiviral vector can generate BCMA-directed CAR T cells inside patients with multiple myeloma
3 min read
Roving Reporter Asks: Is Cell and Gene Therapy Entering a More Mature Phase?
September 25, 2026
IBTV speaks with industry leaders at ASGCT 2026 about the regulatory, manufacturing, investment, and commercialization trends signaling a new phase for advanced therapies
1 min read
MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models
September 24, 2026
Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer
2 min read
